Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B

Citation:

Jang H, Yoon JS, Park SY, Lee HA, Jang MJ, Kim SU, Sinn DH, Seo YS, Kim HY, Kim SE, et al. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol [Internet]. 2022;20:1343-1353 e16.

Website

Contact Details

National and Kapodistrian University of Athens
Medical School, Dept. of Hygiene, Epidemiology and Medical Statistics
Building no. 12
M. Asias 75, 11527 Athens, Greece

Tel. (+30) 210-7462193
email: vsipsa@med.uoa.gr

Recent Publications

High levels of all-cause mortality among people who inject drugs from 2018 to 2022
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions
PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B

2024 (3)
2023 (9)
2022 (22)
2021 (13)
2020 (10)
2019 (5)
2018 (4)
2017 (8)
2016 (2)
2015 (13)

Vana Sypsa

Professor, Medicine

Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B

Citation:

Contact Details

Recent Publications

Publications per year